ATE268477T1 - Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit - Google Patents

Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit

Info

Publication number
ATE268477T1
ATE268477T1 AT00957770T AT00957770T ATE268477T1 AT E268477 T1 ATE268477 T1 AT E268477T1 AT 00957770 T AT00957770 T AT 00957770T AT 00957770 T AT00957770 T AT 00957770T AT E268477 T1 ATE268477 T1 AT E268477T1
Authority
AT
Austria
Prior art keywords
reagent
clotting time
heparin
measuring cartridge
determining clotting
Prior art date
Application number
AT00957770T
Other languages
English (en)
Inventor
Berndt B Bruegger
Original Assignee
Roche Diagnostics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Corp filed Critical Roche Diagnostics Corp
Application granted granted Critical
Publication of ATE268477T1 publication Critical patent/ATE268477T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
AT00957770T 1999-09-03 2000-08-24 Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit ATE268477T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15245099P 1999-09-03 1999-09-03
PCT/US2000/023249 WO2001018551A1 (en) 1999-09-03 2000-08-24 Method, reagent and test cartridge for determining clotting time
US09/645,786 US6699718B1 (en) 1999-09-03 2000-08-24 Method, reagent and test cartridge for determining clotting time

Publications (1)

Publication Number Publication Date
ATE268477T1 true ATE268477T1 (de) 2004-06-15

Family

ID=22542977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957770T ATE268477T1 (de) 1999-09-03 2000-08-24 Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit

Country Status (8)

Country Link
US (2) US6699718B1 (de)
EP (1) EP1208383B1 (de)
AT (1) ATE268477T1 (de)
AU (1) AU6933900A (de)
CA (1) CA2382143C (de)
DE (1) DE60011274T2 (de)
ES (1) ES2222228T3 (de)
WO (1) WO2001018551A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1208383B1 (de) * 1999-09-03 2004-06-02 Roche Diagnostics Corporation Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit
US6448024B1 (en) * 2000-10-03 2002-09-10 Roche Diagnostics Corporation Method, reagent, cartridge, and device for determining fibrinogen
JP3905833B2 (ja) * 2002-12-27 2007-04-18 伊那食品工業株式会社 増粘用添加物
CA2566411A1 (en) * 2004-05-11 2005-11-24 Heptest Laboratories, Inc. Compositions, kit and one-step method for monitoring compounds having anti-factor xa and/or anti factor iia activities
US7674616B2 (en) * 2006-09-14 2010-03-09 Hemosense, Inc. Device and method for measuring properties of a sample
US20080114549A1 (en) * 2006-11-09 2008-05-15 Mark Evan Schafer Rapid response blood analyzer
US20080297169A1 (en) * 2007-05-31 2008-12-04 Greenquist Alfred C Particle Fraction Determination of A Sample
EP2040073A1 (de) 2007-09-20 2009-03-25 Iline Microsystems, S.L. Mikrofluidische Vorrichtung und Verfahren zur Flüssigkeitsgerinnungs-Zeitbestimmung
US8448499B2 (en) 2008-12-23 2013-05-28 C A Casyso Ag Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method
US20100285583A1 (en) * 2009-05-08 2010-11-11 Capelluto Daniel G S Compounds and methods for inhibiting platelet aggregation
WO2011094279A1 (en) * 2010-01-26 2011-08-04 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Planar labyrinth micromixer systems and methods
EP2371284A1 (de) 2010-03-24 2011-10-05 C A Casyso AG Verfahren und Vorrichtung zur Bestimmung von mindestens einem Auswertungsparameter einer Blutprobe
CA2898201C (en) 2012-01-16 2023-09-26 Abram Scientific, Inc. Methods, devices, and systems for measuring physical properties of fluid
JP6153951B2 (ja) 2012-03-16 2017-06-28 スタット−ダイアグノスティカ アンド イノベーション， エス． エル． 統合された移送モジュールを有する試験カートリッジ
US9075042B2 (en) 2012-05-15 2015-07-07 Wellstat Diagnostics, Llc Diagnostic systems and cartridges
US9213043B2 (en) 2012-05-15 2015-12-15 Wellstat Diagnostics, Llc Clinical diagnostic system including instrument and cartridge
US9625465B2 (en) 2012-05-15 2017-04-18 Defined Diagnostics, Llc Clinical diagnostic systems
US9897618B2 (en) 2014-09-29 2018-02-20 C A Casyso Gmbh Blood testing system
US10175225B2 (en) 2014-09-29 2019-01-08 C A Casyso Ag Blood testing system and method
US10288630B2 (en) 2014-09-29 2019-05-14 C A Casyso Gmbh Blood testing system and method
US10539579B2 (en) 2014-09-29 2020-01-21 C A Casyso Gmbh Blood testing system and method
US10816559B2 (en) 2014-09-29 2020-10-27 Ca Casyso Ag Blood testing system and method
USD777343S1 (en) 2015-05-28 2017-01-24 C A Casyso Ag Body fluid cartridge device
US10295554B2 (en) 2015-06-29 2019-05-21 C A Casyso Gmbh Blood testing system and method
DE202015104762U1 (de) * 2015-09-08 2016-12-09 Jürgen Schulz Kartusche für eine Koagulationsmessung
US10473674B2 (en) 2016-08-31 2019-11-12 C A Casyso Gmbh Controlled blood delivery to mixing chamber of a blood testing cartridge
US10843185B2 (en) 2017-07-12 2020-11-24 Ca Casyso Gmbh Autoplatelet cartridge device

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3311287A1 (de) 1983-03-28 1984-10-04 Behringwerke Ag, 3550 Marburg Verfahren zur fotometrischen bestimmung der aktivierten partiellen thromboplastinzeit und reagenz dazu
DE3407280A1 (de) 1984-02-28 1985-09-19 Gödecke AG, 1000 Berlin Testsatz zur bestimmung der aktivierten partiellen thromboplastinzeit (ptt) mit erhoehter heparinempfindlichkeit
DE3504405A1 (de) * 1985-02-08 1986-08-14 Boehringer Mannheim Gmbh, 6800 Mannheim Bestimmung von prokallikrein
US4666831A (en) 1985-02-19 1987-05-19 The Liposome Company, Inc. Lipid-dependent diagnostic assays
US5164598A (en) 1985-08-05 1992-11-17 Biotrack Capillary flow device
US4756884A (en) 1985-08-05 1988-07-12 Biotrack, Inc. Capillary flow device
US4946775A (en) 1985-09-05 1990-08-07 Yin E Thye Composition, kit and method for assaying heparin and a method for making the composition
US4755461A (en) 1986-04-17 1988-07-05 Bio/Data Corporation Tableted blood plasma microconcentrated thromboplastin coagulation reagent
US5039617A (en) * 1989-04-20 1991-08-13 Biotrack, Inc. Capillary flow device and method for measuring activated partial thromboplastin time
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
AT395597B (de) 1991-01-25 1993-01-25 Immuno Ag Reagens zur bestimmung von faktor viii-aktivitaet
US5254350A (en) 1991-07-22 1993-10-19 Helena Laboratories Corporation Method of preparing a thromboplastin extract
JP3180824B2 (ja) 1991-08-30 2001-06-25 シスメックス株式会社 血液凝固試薬
DE69224622T2 (de) * 1991-10-04 1998-11-05 Dade Behring Inc Herstellung von prothrombinzeit-reagenzien aus rekombinantem menschlichem gewebefaktor und sythetischen phospholipiden
DE59309374D1 (de) 1992-05-15 1999-03-25 Immuno Ag Reagens zur Bestimmung der aktivierten partiellen Thromboplastinzeit (aPTT)
US5443959A (en) 1992-09-09 1995-08-22 Tokuyama Corporation Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof
US5472852A (en) 1993-09-15 1995-12-05 Oklahoma Medical Research Foundation Assay for detection of selective Protein C inhibition by patients
EP0677171B1 (de) 1993-11-04 2000-03-29 Dade Behring Inc. Tetrahydroxychinon als eine aktivatorkomponente für den aktivierten partiellen thromboplastinzeit-test der blutgerinnung und als anzeiger von blutgerinnungsstörungen
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
US5705395A (en) 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders
WO1998048283A1 (en) * 1997-04-23 1998-10-29 Instrumentation Laboratory S.P.A. Recombinant rabbit tissue factor based prothrombin time reagent
US6183979B1 (en) * 1999-03-24 2001-02-06 International Technidyne Corporation Preparation of dried synthetic prothrombin time reagents
EP1208383B1 (de) 1999-09-03 2004-06-02 Roche Diagnostics Corporation Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit

Also Published As

Publication number Publication date
ES2222228T3 (es) 2005-02-01
AU6933900A (en) 2001-04-10
EP1208383B1 (de) 2004-06-02
DE60011274D1 (de) 2004-07-08
EP1208383A1 (de) 2002-05-29
US20040077097A1 (en) 2004-04-22
DE60011274T2 (de) 2005-07-07
CA2382143A1 (en) 2001-03-15
US6699718B1 (en) 2004-03-02
WO2001018551A1 (en) 2001-03-15
CA2382143C (en) 2005-10-18

Similar Documents

Publication Publication Date Title
DE60011274D1 (de) Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit
Comerota et al. Operative venodilation: a previously unsuspected factor in the cause of postoperative deep vein thrombosis
DE69920940D1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
Kockum Radioimmunoassay of fibrinopeptide A-Clinical applications
Thompson et al. Single soleus muscle fiber function after hindlimb unweighting in adult and aged rats
Kyrle et al. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man-effect of low-dose aspirin
DE3483085D1 (de) Desulfatohirudine, verfahren zu ihrer herstellung und pharmazeutische mittel.
Hopper et al. Assessment of the effect of dilution of blood samples with sodium heparin on blood gas, electrolyte, and lactate measurements in dogs
DE69230000T2 (de) Verfahren und testsatz zur messung von endogenen zytokinen
ATE378015T1 (de) System zur behandlung eines patienten mit einem medikament zur optimierung der therapie und zur verhinderung eines negativen nebeneffektes
ATE100150T1 (de) Verfahren zur bestimmung von physiologisch wirksamen substanzen.
Orlowski et al. The bone marrow as a source of laboratory studies
DE69431016D1 (de) Verfahren zur "In-vivo"-Messung der Konzentration von xenobiotischen Verbindungen mittels magnetischer Kernresonanz
BR9804648A (pt) Monitorização da obediência do paciente ao tratamento e da biodisponibilidade de drogas pela desproteinização de fluidos corpóreos.
Bergqvist et al. Deep vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factors
Slichter et al. Dysbaric osteonecrosis: a consequence of intravascular bubble formation, endothelial damage, and platelet thrombosis
Bröijersén et al. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII
DE60133510D1 (de) Automatisches Verfahren zur quantitativen Bestimmung und Überwachung von exogenem Hämoglobin in Vollblut, Blutplasma und Blutserum
Compton et al. A micropuncture investigation of electrolyte transport in the parotid glands of sodium‐replete and sodium‐depleted sheep.
Bowers et al. Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.
Dasgupta et al. Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin
Hull et al. Long-term anticoagulant therapy in patients with venous thrombosis
ATE108906T1 (de) Methode zur bestimmung des verhaltens von medikamenten in lebewesen.
JP2954239B2 (ja) 全血用簡易血液凝固能検査用具
Moelleken et al. An adverse wound environment activates leukocytes prematurely

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties